Biogen Idec to Acquire Full Rights and Control of TYSABRI® from Elan for ... The Herald | HeraldOnline.com ... (interferon beta-1a), TYSABRI and RITUXAN® (rituximab), the importance of TYSABRI's sales growth, uncertainty of success in commercializing and developing other products, product competition, the occurrence of adverse safety events with our ... |
